{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T06:43:31Z","timestamp":1781678611879,"version":"3.54.5"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T00:00:00Z","timestamp":1747440000000},"content-version":"am","delay-in-days":289,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"NIMH","doi-asserted-by":"publisher","award":["K08MH123624"],"award-info":[{"award-number":["K08MH123624"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jsatjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Use and Addiction Treatment"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.josat.2024.209363","type":"journal-article","created":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T02:55:03Z","timestamp":1713408903000},"page":"209363","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Composition of buprenorphine prescribing networks in Medicaid and association with quality of care"],"prefix":"10.1016","volume":"163","author":[{"given":"Jane M.","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina J.","family":"Charlesworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley D.","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coleman","family":"Drake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Polsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Todd","family":"Korthuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. John","family":"McConnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.josat.2024.209363_bb0005","author":"American Society of Addiction Medicine"},{"issue":"5","key":"10.1016\/j.josat.2024.209363_bb0010","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/MLR.0000000000001530","article-title":"Quality of buprenorphine care for insured adults with opioid use disorder","volume":"59","author":"Anderson","year":"2021","journal-title":"Medical Care"},{"key":"10.1016\/j.josat.2024.209363_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108548","article-title":"Associations of retention on buprenorphine for opioid use disorder with patient characteristics and models of care in the primary care setting","volume":"131","author":"Bailey","year":"2021","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.josat.2024.209363_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.109089","article-title":"Buprenorphine prescriber monthly patient caseloads: An examination of 6-year trajectories","volume":"228","author":"Cabreros","year":"2021","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.josat.2024.209363_bb0025","author":"Center for Medicare & Medicaid Services"},{"issue":"2","key":"10.1016\/j.josat.2024.209363_bb0030","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1001\/jama.2021.7374","article-title":"Use of medications for treatment of opioid use disorder among US Medicaid enrollees in 11 states, 2014\u20132018","volume":"326","author":"Donahue","year":"2021","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.josat.2024.209363_bb0035","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.4058","article-title":"Changes in buprenorphine prescribing to Medicaid beneficiaries during the first year of the COVID-19 pandemic","volume":"5","author":"Dowd","year":"2022","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.josat.2024.209363_bb0040","series-title":"MMWR. Recommendations and reports","article-title":"CDC clinical practice guideline for prescribing opioids for pain\u2014United States, 2022","volume":"71","author":"Dowell","year":"2022"},{"key":"10.1016\/j.josat.2024.209363_bb0045","article-title":"Patterns of clinic switching and continuity of medication for opioid use disorder in a Medicaid-enrolled population","volume":"221","author":"Drake","year":"2021","journal-title":"Drug and Alcohol Dependence"},{"issue":"8","key":"10.1016\/j.josat.2024.209363_bb0050","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1377\/hlthaff.2019.01559","article-title":"Primary care providers and specialists deliver comparable buprenorphine treatment quality","volume":"39","author":"Gertner","year":"2020","journal-title":"Health Affairs (Project Hope)"},{"issue":"6","key":"10.1016\/j.josat.2024.209363_bb0055","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1097\/ADM.0000000000000164","article-title":"Patterns and quality of buprenorphine opioid agonist treatment in a large Medicaid program","volume":"9","author":"Gordon","year":"2015","journal-title":"Journal of Addiction Medicine"},{"key":"10.1016\/j.josat.2024.209363_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108416","article-title":"Patterns of patient discontinuation from buprenorphine\/naloxone treatment for opioid use disorder: A study of a commercially insured population in Massachusetts","volume":"131","author":"Hasan","year":"2021","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.josat.2024.209363_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108783","article-title":"Characteristics and correlates of U.S. clinicians prescribing buprenorphine for opioid use disorder treatment using expanded authorities during the COVID-19 pandemic","volume":"225","author":"Jones","year":"2021","journal-title":"Drug and Alcohol Dependence"},{"issue":"5","key":"10.1016\/j.josat.2024.209363_bb0070","first-page":"890","article-title":"Physician volume, specialty, and outcomes of care for patients with heart failure","volume":"6","author":"Joynt","year":"2013","journal-title":"Circulation: Heart Failure"},{"key":"10.1016\/j.josat.2024.209363_bb0075","author":"Kaiser Family Foundation"},{"issue":"1","key":"10.1016\/j.josat.2024.209363_bb0080","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1080\/08897077.2022.2060424","article-title":"Sociodemographic differences in quality of treatment to Medicaid enrollees receiving buprenorphine","volume":"43","author":"Landis","year":"2022","journal-title":"Substance Abuse"},{"key":"10.1016\/j.josat.2024.209363_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2022.109510","article-title":"Differences in buprenorphine treatment quality across physician provider specialties","volume":"237","author":"Levin","year":"2022","journal-title":"Drug and Alcohol Dependence"},{"issue":"6","key":"10.1016\/j.josat.2024.209363_bb0090","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2023.1574","article-title":"State- and county-level geographic variation in opioid use disorder, medication treatment, and opioid-related overdose among Medicaid enrollees","volume":"4","author":"Lindner","year":"2023","journal-title":"JAMA Health Forum"},{"issue":"20","key":"10.1016\/j.josat.2024.209363_bb0095","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1001\/jama.2023.5038","article-title":"Changes in waivered clinicians prescribing buprenorphine and prescription volume by patient limit","volume":"329","author":"Luo","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.josat.2024.209363_bb0100","unstructured":"Medicaid.gov. (n.d.). Substance use disorders. Retrieved December 18, 2023, from https:\/\/www.medicaid.gov\/medicaid\/benefits\/behavioral-health-services\/substance-use-disorders\/index.html."},{"key":"10.1016\/j.josat.2024.209363_bb0105","series-title":"Interpreting the volume-outcome relationship in the context of health care quality: Workshop summary","author":"National Academies of Sciences","year":"2000"},{"key":"10.1016\/j.josat.2024.209363_bb0110","author":"National Quality Forum"},{"issue":"3","key":"10.1016\/j.josat.2024.209363_bb0115","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1001\/jama.2019.18913","article-title":"Trends in buprenorphine treatment in the United States, 2009-2018","volume":"323","author":"Olfson","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.josat.2024.209363_bb0120","series-title":"A look at substance use disorders (SUD) among Medicaid enrollees","author":"Saunders","year":"2023"},{"key":"10.1016\/j.josat.2024.209363_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108513","article-title":"Medicaid participation among practitioners authorized to prescribe buprenorphine","volume":"133","author":"Saunders","year":"2022","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.josat.2024.209363_bb0130","series-title":"Demographics and health insurance coverage of nonelderly adults with mental illness and substance use disorders in 2020","author":"Saunders","year":"2022"},{"issue":"4","key":"10.1016\/j.josat.2024.209363_bb0135","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1001\/jamaoncol.2015.6125","article-title":"Effects of narrow networks on access to high-quality cancer care","volume":"2","author":"Schleicher","year":"2016","journal-title":"JAMA Oncology"},{"issue":"2","key":"10.1016\/j.josat.2024.209363_bb0140","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1215\/03616878-3476117","article-title":"Measuring Medicaid physician participation rates and implications for policy","volume":"41","author":"Sommers","year":"2016","journal-title":"Journal of Health Politics, Policy and Law"},{"issue":"21","key":"10.1016\/j.josat.2024.209363_bb0145","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1001\/jama.2021.4469","article-title":"Concentration of patient care among buprenorphine-prescribing clinicians in the US","volume":"325","author":"Stein","year":"2021","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.josat.2024.209363_bb0150","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/ajad.13268","article-title":"Buprenorphine treatment retention and comorbidities among patients with opioid use disorder in a primary care setting","volume":"31","author":"Sweeney","year":"2022","journal-title":"The American Journal on Addictions"},{"key":"10.1016\/j.josat.2024.209363_bb0155","author":"The White House"},{"key":"10.1016\/j.josat.2024.209363_bb0160","author":"University of California San Diego"},{"issue":"4","key":"10.1016\/j.josat.2024.209363_bb0165","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.2727","article-title":"Comparison of office-based physician participation in Medicaid managed care and health insurance exchange plans in the same US geographic markets","volume":"3","author":"Wallace","year":"2020","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.josat.2024.209363_bb0170","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jsat.2016.12.010","article-title":"Long-term retention in office based opioid treatment with buprenorphine","volume":"74","author":"Weinstein","year":"2017","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"5","key":"10.1016\/j.josat.2024.209363_bb0175","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.2943","article-title":"Association of buprenorphine-waivered physician supply with buprenorphine treatment use and prescription opioid use in Medicaid enrollees","volume":"1","author":"Wen","year":"2018","journal-title":"JAMA Network Open"},{"issue":"1","key":"10.1016\/j.josat.2024.209363_bb0180","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s13181-020-00795-3","article-title":"Opioid overdose deaths with buprenorphine detected in postmortem toxicology: A retrospective analysis","volume":"17","author":"Wightman","year":"2021","journal-title":"Journal of Medical Toxicology"},{"issue":"27","key":"10.1016\/j.josat.2024.209363_bb0185","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1200\/JCO.2017.73.2040","article-title":"Relation between narrow networks and providers of cancer care","volume":"35","author":"Yasaitis","year":"2017","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1016\/j.josat.2024.209363_bb0190","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2021.0280","article-title":"Medicaid managed care network adequacy standards for mental health care access: Balancing flexibility and accountability","volume":"2","author":"Zhu","year":"2021","journal-title":"JAMA Health Forum"},{"key":"10.1016\/j.josat.2024.209363_bb0195","article-title":"Characteristics of specialty mental health provider networks in Oregon Medicaid","author":"Zhu","year":"2022","journal-title":"Psychiatric Services"},{"issue":"7","key":"10.1016\/j.josat.2024.209363_bb0200","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1377\/hlthaff.2022.01547","article-title":"Psychiatrist networks in Medicare advantage plans are substantially narrower than in Medicaid and ACA markets","volume":"42","author":"Zhu","year":"2023","journal-title":"Health Affairs (Project Hope)"},{"issue":"9","key":"10.1016\/j.josat.2024.209363_bb0205","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1377\/hlthaff.2017.0325","article-title":"Networks in ACA marketplaces are narrower for mental health care than for primary care","volume":"36","author":"Zhu","year":"2017","journal-title":"Health Affairs (Project Hope)"}],"container-title":["Journal of Substance Use and Addiction Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875924000754?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875924000754?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T05:16:01Z","timestamp":1728623761000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949875924000754"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":41,"alternative-id":["S2949875924000754"],"URL":"https:\/\/doi.org\/10.1016\/j.josat.2024.209363","relation":{},"ISSN":["2949-8759"],"issn-type":[{"value":"2949-8759","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Composition of buprenorphine prescribing networks in Medicaid and association with quality of care","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Use and Addiction Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.josat.2024.209363","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"209363"}}